植入物乳房再造术后阿片类药物与镇静剂的共同处方
该研究利用医保索赔数据,分析2008年1月至2019年6月间接受植入物乳房再造的18至64岁女性,评估阿片类药物与骨骼肌松弛剂或苯二氮䓬类共同处方的频率及相关因素。结果显示86.7%患者围手术期配取阿片类药物,其中27.7%共同配取苯二氮䓬类、14.4%共同配取骨骼肌松弛剂、2.4%三者均配取;共同处方与阿片类药物再配取显著相关。作者认为应避免此类共同处方。
要点
- 86.7%的植入物乳房再造女性围手术期配取阿片类药物。
- 27.7%共同配取苯二氮䓬类,14.4%共同配取骨骼肌松弛剂,2.4%三者均配取。
- 共同处方者阿片类药物再配取显著增加,即使控制术前阿片暴露。
核心结论
- 近半数女性在植入物乳房再造后配取阿片类药物同时配取苯二氮䓬类、骨骼肌松弛剂或两者。
- 阿片类药物与骨骼肌松弛剂共同处方可能加剧术后阿片类药物使用,鉴于镇静风险应避免。
- 识别避免使用镇静剂管理乳房再造后疼痛的策略对减少高风险处方行为至关重要。
研究设计与样本
- 基于医疗索赔数据的回顾性分析,纳入2008年1月至2019年6月期间接受植入物乳房再造的18至64岁女性。
- 评估共同处方频率、与共同处方阿片类药物和骨骼肌松弛剂或苯二氮䓬类相关的因素,以及对再造后90天内阿片类药物再配取的影响。
主要发现
- 86.7%的女性(n=7574)在植入物乳房再造围手术期配取了阿片类药物处方。
- 27.7%的女性配取了阿片类药物和苯二氮䓬类处方,14.4%配取了阿片类药物和骨骼肌松弛剂处方,2.4%配取了阿片类药物、苯二氮䓬类和骨骼肌松弛剂处方。
- 共同处方阿片类药物和苯二氮䓬类的风险因素包括使用脱细胞真皮基质、即刻再造和焦虑史。
- 配取阿片类药物和骨骼肌松弛剂、阿片类药物和苯二氮䓬类、以及阿片类药物联合骨骼肌松弛剂和苯二氮䓬类处方的女性显著更可能再配取阿片类药物处方,即使控制术前阿片类药物暴露。
临床怎么用
- 作者认为,鉴于镇静风险,应避免阿片类药物与骨骼肌松弛剂共同处方。
- 作者认为,识别避免使用镇静剂管理乳房再造后疼痛的策略对减少高风险处方行为至关重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Skeletal muscle relaxants and benzodiazepines are thought to mitigate against postoperative muscle contraction. The Centers for Disease Control and Prevention and the Food and Drug Administration warn against coprescribing them with opioids because of increased risks of overdose and death. The authors evaluated the frequency of coprescribing of opioids with skeletal muscle relaxants or benzodiazepines after implant-based reconstruction. METHODS: The authors examined health care claims to identify women (18 to 64 years old) who underwent implant-based breast reconstruction between January of 2008 and June of 2019 to determine the frequency of coprescribing, factors associated with coprescribing opioids and skeletal muscle relaxants or benzodiazepines, and the impact on opioid refills within 90 days of reconstruction. RESULTS: A total of 86.7 percent of women ( n = 7574) who had implant-based breast reconstruction filled an opioid prescription perioperatively. Of these, 27.7 percent of women filled prescriptions for opioids and benzodiazepines, 14.4 percent for opioids and skeletal muscle relaxants, and 2.4 percent for opioids, benzodiazepines, and skeletal muscle relaxants. Risk factors for coprescribing opioids and benzodiazepines included use of acellular dermal matrix, immediate reconstruction, and history of anxiety. Women who filled prescriptions for opioids and skeletal muscle relaxants, opioids and benzodiazepines, and opioids with skeletal muscle relaxants and benzodiazepines were significantly more likely to refill opioid prescriptions, even when controlling for preoperative opioid exposure. CONCLUSIONS: Nearly half of women filled an opioid prescription with a benzodiazepine, skeletal muscle relaxant, or both after implant-based breast reconstruction. Coprescribing of opioids with skeletal muscle relaxants may potentiate opioid use after surgery and should be avoided given the risks of sedation. Identifying strategies that avoid sedatives to manage pain after breast reconstruction is critical to mitigate high-risk prescribing practices. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.
引用
- Santosa KB, Wang CS, Hu HM, et al. Opioid Coprescribing with Sedatives after Implant-Based Breast Reconstruction. Plast Reconstr Surg. 2022. PMID: 36103669. doi:10.1097/PRS.0000000000009726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。